Centessa Pharmaceuticals plc
CNTA
$39.59
-$0.02-0.05%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -66.16M | -54.89M | -50.34M | -26.14M | -111.33M |
| Total Depreciation and Amortization | -359.00K | 237.00K | 226.00K | 217.00K | -370.00K |
| Total Amortization of Deferred Charges | 879.00K | 271.00K | 293.00K | 312.00K | 600.00K |
| Total Other Non-Cash Items | 8.62M | 7.34M | 8.92M | 6.80M | 43.12M |
| Change in Net Operating Assets | 1.22M | -11.26M | 18.45M | -38.44M | 25.18M |
| Cash from Operations | -55.81M | -58.31M | -22.45M | -57.25M | -42.80M |
| Capital Expenditure | -11.00K | -234.00K | -126.00K | -- | 0.00 |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -218.12M | 62.18M | -39.83M | -222.39M | 25.00M |
| Cash from Investing | -218.13M | 61.95M | -39.95M | -222.39M | 25.00M |
| Total Debt Issued | -- | -- | -- | -- | 109.34M |
| Total Debt Repaid | -- | -- | -- | -- | -110.10M |
| Issuance of Common Stock | 283.58M | 3.56M | 1.71M | 7.87M | 5.31M |
| Repurchase of Common Stock | -176.00K | -125.00K | -4.49M | -- | -1.59M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -5.00K | 0.00 | 4.39M | -4.79M | -- |
| Cash from Financing | 283.40M | 3.44M | 1.61M | 3.09M | 2.96M |
| Foreign Exchange rate Adjustments | 1.68M | -501.00K | -113.00K | -1.52M | 3.03M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 11.14M | 6.57M | -60.91M | -278.07M | -11.81M |